SEP 21, 2017 2:43 PM PDT

Leveraging Probiotics to Fight Colorectal Cancer

WRITTEN BY: Xuan Pham

Image credit: Pixabay.com

The gut microbiome is increasingly recognized as a vital player in the development of colon cancer. But good bacteria, scientists say, can help us turn the tide against the insidious disease.

The microbiome is a specialized collection of bacteria residing in specialized niches of the body. Mostly famous for their existence in the human gut, these communities of microorganisms have been known to influence processes like digestion and immune responses. The gut microbiota, in particular, has been linked to inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis. In turn, these diseases increase the risk for colon cancer.

Colon cancer, also known as colon cancer or bowel cancer, is the third most common non-skin cancer type in the world. The cancer usually begins as small, benign lumps of cells that form polyps in the colon. Without proper removal, these polyps can turn cancerous and cause symptoms such as abdominal pain, rectal bleeding, weakness, and fatigue. According to a recent report, the incidence of colorectal cancer is expected to increase by 60% to more than 2.2 million new cases and 1.1 million deaths by 2030.

Could good bacteria, AKA probiotics, lower the risk for colon cancer?

In the current study, scientists at the Baylor College of Medicine in Houston, Texas, focused on the effects of Lactobacillus reuteri, which is a probiotic naturally found in the guts of mammals.

The team injected L. reuteri into mice that were deficient in an enzyme called histidine decarboxylase (HDC). Without HDC, these mice are much more susceptible to develop colorectal cancer. By contrast, one of the roles of L. reuteri involves producing the enzyme HDC.

In mice treated with the probiotic, the team found less tumors, and the ones they did find were smaller in size. By contrast, animals that received the placebo treatment had more numerous and larger tumors. The results suggest the probiotic L. reuteri has protective effects against colorectal tumor formation.

"Our results suggest a significant role for histamine in the suppression of chronic intestinal inflammation and colorectal tumorigenesis [tumor formation]," says Dr. James Versalovic, a professor of pathology and immunology at Baylor, and the study’s lead author. "We have also shown that cells, both microbial and mammalian, can share metabolites or chemical compounds that together promote human health and prevent disease."

“We are on the cusp of harnessing advances in microbiome science to facilitate diagnosis and treatment of human disease. By simply introducing microbes that provide missing life substances, we can reduce the risk of cancer and supplement diet-based cancer prevention strategies,” he added.

Additional sources: MNT

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
SEP 21, 2020
Cancer
The Protein ETV1 May Act as a Biomarker for Gastrointestinal Cancer
SEP 21, 2020
The Protein ETV1 May Act as a Biomarker for Gastrointestinal Cancer
Cancer is an incredibly diverse disease. It has many types and even sub-types, with a vast range of characteristics. Som ...
OCT 15, 2020
Cancer
How is mole growth really associated to skin cancer?
OCT 15, 2020
How is mole growth really associated to skin cancer?
New research published in the journal eLife questions the way we think about skin cancer. Focused on mole growth, the st ...
OCT 18, 2020
Cancer
Virus-mimicking drug attacks melanoma tumors
OCT 18, 2020
Virus-mimicking drug attacks melanoma tumors
Research published recently in the journal Science Translational Medicine from scientists at the UCLA Jonsson Compr ...
OCT 30, 2020
Cancer
Fighting mesothelioma with curcumin
OCT 30, 2020
Fighting mesothelioma with curcumin
Research led by investigators at Flinders University in Australia is spearheading new developments in cancer prevention ...
NOV 11, 2020
Cancer
A New CDK Inhibitor Could Help with Unresponsive Liver Cancer
NOV 11, 2020
A New CDK Inhibitor Could Help with Unresponsive Liver Cancer
Amongst the most common targets of anti-cancer drugs are small regulatory molecules called cyclin-dependent kinases (CDK ...
NOV 25, 2020
Cancer
Using RNA to Diagnose HPV Associated Cancer
NOV 25, 2020
Using RNA to Diagnose HPV Associated Cancer
Diagnostic tools are critical to modern medicine. They might be less exciting than a good therapy or drug, but doctors a ...
Loading Comments...